CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

GlobeNewswire Pharma
Original article

Ascendis Announces Planned $400 Million Share Repurchase Program

Neutral
AI Analysis

Summary

Ascendis Pharma's Board of Directors authorized a $400 million share repurchase program. The program allows the company to buy back its ordinary shares as part of its capital allocation strategy.

Importance:3/10
Sentiment:
0.20
share_repurchasecapital_allocationshareholder_return
Related Companies

Read the original article

Published by GlobeNewswire Pharma on September 14, 2026 10:00 PM

Read Original